Published on : Jun 30, 2017
Albany, New York, June 30, 2017: Use of acyl-CoA desaturase for maintaining structure and function of membranes within the cells of the organism acts as the reason for its wide use. To detail the pipeline overview, Market Research Hub (MRH) has reported a new report focusing on acyl-CoA desaturase in the research study titled as “Acyl-CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl-CoA Desaturase or SCD or EC 18.104.22.168) - Pipeline Review, H1 2017” to its vast report database.
Acyl-CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl-CoA Desaturase or SCD or EC 22.214.171.124) - Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. It is an important enzyme in fatty acid metabolism and is involved in the regulation of inflammation and stress in distinct cell types, including cells, adipocytes, macrophages, endothelial cells, and myocytes. The complete loss of this fatty acid desaturase has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis. The report goes on to cover products from therapy areas like Gastrointestinal, Oncology and Infectious Disease which include indications Non-Alcoholic Steatohepatitis (NASH), Colorectal Cancer, Metabolic Disorders, HIV-Associated Lipodystrophy Syndrome, Liver Fibrosis, Metastatic Renal Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD) and Obesity.
The research outlays comprehensive information on the Acyl-CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl-CoA Desaturase or SCD or EC 126.96.36.199) targeted therapeutics development, completed with analysis by stage of development, indication, mechanism of action (MoA), route of administration (RoA), molecule type and development by companies. Furthermore, it reviews the key players involved in Acyl-CoA Desaturase targeted therapeutics development with respective active and dormant or discontinued projects. The main companies featured in the therapeutic development are Daiichi Sankyo Company Ltd, Galmed Pharmaceuticals Ltd, Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Company Ltd.
Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157708
Moreover, the drugs are also profiled along with the product description, mechanism of action, R&D progress with main drugs including Aramchol, Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis, Small Molecule to Inhibit SCD1 for Metabolic Disorders, Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity, Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma, and T-3764518. Lastly, the report has various news and press release links that are related to the pipeline review of the acyl-CoA desaturase and finally concludes with the detailed primary research, secondary research, and expert panel validation analysis which give a trustful overview and help in easy decision making by the experts.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com